187 related articles for article (PubMed ID: 15968108)
1. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
Zannettino AC; Farrugia AN; To LB; Atkins GJ
Methods Mol Med; 2005; 113():245-56. PubMed ID: 15968108
[TBL] [Abstract][Full Text] [Related]
2. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
[TBL] [Abstract][Full Text] [Related]
4. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
[TBL] [Abstract][Full Text] [Related]
5. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
[TBL] [Abstract][Full Text] [Related]
6. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
[TBL] [Abstract][Full Text] [Related]
7. Osteoclast culture and resorption assays.
Bradley EW; Oursler MJ
Methods Mol Biol; 2008; 455():19-35. PubMed ID: 18463808
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of myeloma bone disease.
Roodman GD
Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
[TBL] [Abstract][Full Text] [Related]
9. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
Adamopoulos IE; Wordsworth PB; Edwards JR; Ferguson DJ; Athanasou NA
Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of bone lesions in multiple myeloma.
Bataille R; Chappard D; Klein B
Hematol Oncol Clin North Am; 1992 Apr; 6(2):285-95. PubMed ID: 1582975
[TBL] [Abstract][Full Text] [Related]
12. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease.
Brunetti G; Colucci S; Rizzi R; Mori G; Colaianni G; Oranger A; Zallone A; Liso V; Grano M
Ann N Y Acad Sci; 2006 Apr; 1068():334-40. PubMed ID: 16831934
[TBL] [Abstract][Full Text] [Related]
13. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
15. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
16. Characterization of in vitro growth of multiple myeloma cells.
Zlei M; Egert S; Wider D; Ihorst G; Wäsch R; Engelhardt M
Exp Hematol; 2007 Oct; 35(10):1550-61. PubMed ID: 17889722
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies for bone disease.
Roodman GD
Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
[TBL] [Abstract][Full Text] [Related]
18. Synovial fluid macrophages are capable of osteoclast formation and resorption.
Adamopoulos IE; Sabokbar A; Wordsworth BP; Carr A; Ferguson DJ; Athanasou NA
J Pathol; 2006 Jan; 208(1):35-43. PubMed ID: 16278818
[TBL] [Abstract][Full Text] [Related]
19. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
20. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.
Colucci S; Brunetti G; Mori G; Oranger A; Centonze M; Mori C; Cantatore FP; Tamma R; Rizzi R; Liso V; Zallone A; Grano M
Leukemia; 2009 Nov; 23(11):2139-46. PubMed ID: 19587706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]